City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Lycia Therapeutics targets $938 million valuation in US IPO

Drug developer Lycia Therapeutics announced it is targeting a valuation of up to $937.7 million in its U.S. initial public offering, joining other biotech companies entering the IPO market.